Advertisement

Die Infektiologie pp 1286-1362 | Cite as

Infektionen bei speziellen Patienten

  • R. Abel
  • M. Backmund
  • G. Caspari
  • D. Eichenlaub
  • K. Hager
  • E.-R. Kuse
  • H. Link
Chapter
  • 141 Downloads

Zusammenfassung

Die zytostatische Chemotherapie bösartiger Erkrankungen führt häufig zum Abfall der neutrophilen Granulozyten und zur mehrtägigen Granulozytopenie bzw. Neutropenie. Das Risiko einer Infektion nimmt unterhalb von 1000 neutrophilen Granulozyten pro Mikroliter signifikant zu. Ausmaß und Dauer der Neutropenie beeinflussen ebenfalls die Wahrscheinlichkeit von Infektionen. Patienten mit einer länger als 10 Tage anhaltenden schweren Neutropenie (<100l) entwickeln in 80% der Fälle Infektionen.

Literatur

  1. 1.
    Hughes WT, Armstrong D, Bodey G et al. (1997) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551–573PubMedCrossRefGoogle Scholar
  2. 2.
    Link H, Maschmeyer G, Meyer P et al. (1994) Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol 69:231–243PubMedCrossRefGoogle Scholar
  3. 3.
    Link H, Hiddemann W, Maschmeyer G et al. (1997) Antimicrobial therapy in neutropenic patients with unexplained fever, PEG-Study II. Onkologie 20:S 1–132CrossRefGoogle Scholar
  4. 4.
    Cometta A, Zinner S, De Bock R et al. (1995) Piperacillin-tazobactam plus amikacin vs. ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39/2:445–452PubMedGoogle Scholar
  5. 5.
    Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332PubMedCrossRefGoogle Scholar
  6. 6.
    Klastersky J, Glauser MP, Schimpff SC et al. (1986) EORTC Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 29:263–270PubMedGoogle Scholar
  7. 7.
    de Pauw BE, Deresinski SC, Feld R et al. (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 120:834–844PubMedGoogle Scholar
  8. 8.
    Shenep JL, Hughes WT, Roberson PK et al. (1988) Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 319:1053–1058PubMedCrossRefGoogle Scholar
  9. 9.
    Elting LS, Bodey GP, Keefe BH (1992) Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors. Clin Infect Dis 14:1201–1207PubMedCrossRefGoogle Scholar
  10. 10.
    Murray BE (2000) Vancomycin-resistant enterococcal infections. N Engl J Med 342/10:710–721PubMedCrossRefGoogle Scholar
  11. 11.
    Pizzo PA, Ladisch S, Robichaud K (1980) Treatment of grampositive septicemia in cancer patients. Cancer 45:206–207PubMedCrossRefGoogle Scholar
  12. 12.
    Maschmeyer G, Link H, Hiddemann W et al. (1994) Pulmonary infiltrations in febrile neutropenic patients. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 73:2296–2304PubMedCrossRefGoogle Scholar
  13. 13.
    Freifeld A, Marchigiani D, Walsh T et al. (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy [see comments]. N Engl J Med 341/5:305–311PubMedCrossRefGoogle Scholar
  14. 14.
    Kern WV, Cometta A, De Bock R et al. (1999) Oral vs. intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer [see comments]. N Engl J Med 341(5): 312–318PubMedCrossRefGoogle Scholar
  15. 15.
    Gilbert DN, Dworkin RJ, Raber SR, Leggett JE (1997) Outpatient parenteral antimicrobial-drug therapy. N Engl J Med 337/12:829–838PubMedCrossRefGoogle Scholar
  16. 16.
    Hidalgo M, Hornedo J, Lumbreras C et al. (1999) Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 85/1:213–219PubMedCrossRefGoogle Scholar
  17. 17.
    Uzun O, Anaissie EJ (1999) Outpatient therapy for febrile neutropenia: Who, when, and how? J Antimicrob Chemother 43/3:317–320PubMedCrossRefGoogle Scholar
  18. 18.
    Klastersky J, Paesmans M, Rubenstein EB et al. (2000) The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18/16:3038–3051PubMedGoogle Scholar
  19. 19.
    Link H, Blumenstengel K, Bohme A et al. (1999) Antimicrobial therapy for fever of unknown origin in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology. Dtsch Med Wochenschr 124(Suppl 1): S3–S8PubMedGoogle Scholar
  20. 20.
    Kern WV Beyer J Bohme A et al. 2000 Prophylaxis of infection in neutropenic patients. Guidelines of the Working Party on Infections in Hematology and Oncology. Dtsch Med Wochenschr 125/51–52: 1582–15PubMedCrossRefGoogle Scholar
  21. 21.
    Fatkenheuer G, Buchheidt D, Fuhr HG et al. (2001) Venous catheterassociated infections in patients with neutropenia. Dtsch Med Wochenschr 126/4:89–95PubMedCrossRefGoogle Scholar
  22. 22.
    Ostermann H, Derigs HG, Heussel G et al. (1999) Sepsis in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association for Hematology and Oncology. Dtsch Med Wochenschr 124(Suppl 1):S14–S17PubMedGoogle Scholar
  23. 23.
    Bohme A, Karthaus M, Einsele H et al. (1999) Diagnosis of systemic fungal infection in hematology. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association for Hematology and Oncology. Dtsch Med Wochenschr 124(Suppl 1): S24–S30PubMedGoogle Scholar
  24. 24.
    Hughes WT, Armstrong D, Bodey GP et al. (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381–396PubMedCrossRefGoogle Scholar
  25. 25.
    Bodey GP, Jadeja L, Elting L (1985) Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145/9:1621–1629PubMedCrossRefGoogle Scholar
  26. 26.
    Bodey GP, Elting L, Kassamali H, Lim BP (1986) Escherichia coli bacteremia in cancer patients. Am J Med 81/1 A: 85–95PubMedCrossRefGoogle Scholar
  27. 27.
    Bochud P-Y, Calandra T, Francioli P (1994) Bacteremia due to viridans streptococci: a review. Am J Med 97:256–264PubMedCrossRefGoogle Scholar
  28. 28.
    Klastersky J, Zinner SH (1982) Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 4:294–301PubMedCrossRefGoogle Scholar
  29. 29.
    EORTC, International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317:1692–1698CrossRefGoogle Scholar
  30. 30.
    Anaissie EJ, Vartivarian SE, Abi-Said D et al. (1996) Fluconazole vs. amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 101/2:170–176PubMedCrossRefGoogle Scholar
  31. 31.
    Anaissie EJ, Darouiche RO, Abi-Said D et al. (1996) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole vs. amphotericin B and review of the literature. Clin Infect Dis 23/5:964–972PubMedCrossRefGoogle Scholar
  32. 32.
    Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC (2000) A multicenter, randomized trial of fluconazole vs. amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108/4:282–289PubMedCrossRefGoogle Scholar
  33. 33.
    Walsh TJ, Finberg RW, Arndt C et al. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340/10:764–771PubMedCrossRefGoogle Scholar
  34. 34.
    Wingard JR, White MH, Anaissie E et al. (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B vs. amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31/5:1155–1163PubMedCrossRefGoogle Scholar
  35. 35.
    Schoffski P, Freund M, Wunder R et al. (1998) Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 317/7155:379–384PubMedGoogle Scholar
  36. 36.
    Boogaerts M, Winston DJ, Bow EJ et al. (2001) Intravenous and oral itraconazole vs. intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135/6:412–422PubMedGoogle Scholar
  37. 37.
    Caillot D, Bassaris H, McGeer A et al. (2001) Intravenous Itraconazole Followed by Oral Itraconazole in the Treatment of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies, Chronic Granulomatous Disease, or AIDS. Clin Infect Dis 33/8Google Scholar
  38. 38.
    Boogaerts MA, Maertens J, Bosly A et al. (2001) Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 45/3:981–985PubMedCrossRefGoogle Scholar
  39. 39.
    Walsh TJ, Viviani MA, Arathoon E et al. (2000) New targets and delivery systems for antifungal therapy. Med Mycol 38(Suppl 1):335–347PubMedGoogle Scholar
  40. 40.
    Schimpff SC, Satterlee W, Young VM, Serpick A (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284:1061–1065PubMedCrossRefGoogle Scholar
  41. 41.
    Link H, Maschmeyer G, Meyer P et al. (1996) Antimicrobial therapy in febrile neutropenic patients Results of the prospective studies of the Paul Ehrlich Society for Chemotherapy. Antiinfect Drugs Chemother 14/1:34, A21Google Scholar
  42. 42.
    Giamarellos-Bourboulis EJ, Grecka P et al. (2001), Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 32/12:1718–1725PubMedCrossRefGoogle Scholar
  43. 43.
    Joshi JH, Schimpff SC, Tenney JH, Newman KA, Dejongh CA (1984) Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients?. Am J Med 76:450PubMedCrossRefGoogle Scholar
  44. 44.
    Felzmann T, Gisslinger H, Ludwig H (1994) Immunological findings in patients with myelodysplastic syndrome. Leuk Lymphoma 15/3—4:201–208PubMedCrossRefGoogle Scholar
  45. 45.
    Hamblin TJ et al. (1996) Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33/2:150–162PubMedGoogle Scholar
  46. 46.
    Hofmann WK, Ottmann OG, Ganser A, Hoelzer Deal (1996) Myelodysplastische Syndrome: Clinical features. Semin Hematol 33(3):177–182PubMedGoogle Scholar
  47. 47.
    Cunningham I, MacCallum SJ, Nicholls MD et al. (1995) The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol 90/3:602–606PubMedCrossRefGoogle Scholar
  48. 48.
    Camitta BM, Storb R, Thomas ED (1982) Aplastic Anemia. Pathogenesis, diagnosis, treatment and prognosis. N Engl J Med 306:645–652PubMedCrossRefGoogle Scholar
  49. 49.
    Gluckman E, Esperou-Bourdeau H, Baruchel A et al. (1992) Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood 79:2540–2546PubMedGoogle Scholar
  50. 50.
    (Anonymous) (1987) Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood 70/6:1718–1721Google Scholar
  51. 51.
    Weinberger M (1993) Approach to management of fever and infection in patients with primary bone marrow failure and hemoglobinopathies. Hematol Oncol Clin North Am 7/4:865–885PubMedGoogle Scholar
  52. 52.
    Marsh JC, Socie G, Schrezenmeier H et al. (1994) Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet 344(8916): 172–173PubMedCrossRefGoogle Scholar
  53. 53.
    Frickhofen N, Kaltwasser JP, Schrezenmeier H et al. (1991) Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group [see comments]. N Engl J Med 324:1297–1304PubMedCrossRefGoogle Scholar
  54. 54.
    Bunch C (1987) Management of infection in chronic lymphocytic leukemia. In: Gale RP, Rai KR (eds) Chronic lymphocytic leukemia: recent progress, future advances. A.R. Liss, New York, pp 373–381Google Scholar
  55. 55.
    Cooperative Group for the Study of Immunoglobulin in CLL (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 319:902–907CrossRefGoogle Scholar
  56. 56.
    Chapel H, Dicato M, Gamm H et al. (1994) Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 88/1:209–212PubMedCrossRefGoogle Scholar
  57. 57.
    Jurlander J, Geisler CH, Hansen MM (1994) Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 53/2:114–118PubMedCrossRefGoogle Scholar
  58. 58.
    Weeks JC, Tierney MR, Weinstein MC (1991) Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia [see comments]. N Engl J Med 325/2:81–86PubMedCrossRefGoogle Scholar
  59. 59.
    Calenda V, Chermann JC (1992) The effects of HIV on hematopoiesis. EurJ Haematol 48:181–186CrossRefGoogle Scholar
  60. 60.
    Furman A, Sepkowitz KA, Soave R (1996) Acquired immunodeficiency syndrome. A practical approach to infectios diseases, zz, Boston, pp 725–726Google Scholar
  61. 61.
    Centers for disease control and prevention (1995) Drug regimen for adults and adolescents. MMWR 44(RR-8): 24–25Google Scholar
  62. 62.
    Weite K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): The first 10 years. Blood 88/6:1907–1929Google Scholar
  63. 63.
    American Society of Clinical Oncology (1994) American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12/11:2471–2508Google Scholar
  64. 64.
    Link H, Herrmann F, Weite K et al. (1994) Rationale Therapie mit G-CSF und GM-CSF. Med Klin 89:429–441Google Scholar
  65. 65.
    (Anonymous) (1996) Update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14:1957–1960Google Scholar
  66. 66.
    Link H, Hess CF, Albers P et al. (2001) Rationale Therapie mit den hämatopoetischen Wachstumsfaktoren G-CSF und GM-CSF. Arbeitsgemeinschaft Supportivtherapie (AK-SUPPO) der Deutschen Krebsgesellschaft (DKG). Der Onkologe 7:1329–1340CrossRefGoogle Scholar
  67. 67.
    Grigg A, Vecchi L, Bardy P, Szer J (1996) G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepsis. Aust N Z J Med 26/6:813–818PubMedGoogle Scholar
  68. 68.
    Bhatia S, McCullough J, Perry EH et al. (1994) Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 34/3:226–232PubMedCrossRefGoogle Scholar
  69. 69.
    Clift RA et al. (1978) Granulocyte transfusions for the prevention of infection in patients receiving bone marrow transplantation. N Engl J Med 298:1052–1057PubMedCrossRefGoogle Scholar
  70. 70.
    Sleijfer DT, Mulder NH, de Vries-Hospers HG et al. (1980) Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer 16:859–869PubMedGoogle Scholar
  71. 71.
    Donnelly JP, Maschmeyer G, Daenen S (1992) Selective oral antimicrobial prophylaxis for the prevention of infection in acute lukemia —ciprofloxacin vs. co-trimoxazole plus colistin. Eur J Cancer 28A: 873–878PubMedCrossRefGoogle Scholar
  72. 72.
    Slavin MA, Osborne B, Adams R et al. (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 171/6:1545–1552PubMedCrossRefGoogle Scholar
  73. 73.
    Hansen JA, Gooley TA, Martin PJ et al. (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968PubMedCrossRefGoogle Scholar
  74. 74.
    Winston DJ, Chandrasekar PH, Lazarus HM et al. (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial [see comments]. Ann Intern Med 118/7:495–503PubMedGoogle Scholar
  75. 75.
    Kanda Y, Yamamoto R, Chizuka A et al. (2000) Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 89/7:1611–1625PubMedCrossRefGoogle Scholar
  76. 76.
    Boogaerts M, Maertens J, van Hoof A et al. (2001) Itraconazole vs. amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48/1:97–103PubMedCrossRefGoogle Scholar
  77. 77.
    Hughes WT, Smith BL (1983) Intermittent chemoprophylaxis for pneumocystis carinii pneumonia. Antimicrob Agents Chemother 24:300–103PubMedGoogle Scholar
  78. 78.
    Link H, Vöhringer HF, Wingen F et al. (1993) Pentamidine aerosol for prophylaxis of pneumocystis carinii pneumonia after bone marrow transplantation. Bone Marrow Transplant 11:403–406PubMedGoogle Scholar
  79. 79.
    Anderson H, Scarffe JH, Sutton RN et al. (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomized double-blind, placebo controlled trial. Br J Cancer 50:45–49PubMedCrossRefGoogle Scholar
  80. 80.
    Bowden RA, Sayers M, Gleaves CA et al. (1987) Cytomegalovirusseronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Transfusion 27:478–481PubMedCrossRefGoogle Scholar
  81. 81.
    De Graan-Hentzen YCE, Gratama JW, Mudde GC et al. (1989) Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white blood cell depletion of blood products. Transfusion 29:757–760PubMedCrossRefGoogle Scholar
  82. 82.
    Sullivan KM, Kopecky KJ, Jocom J et al. (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705–712PubMedCrossRefGoogle Scholar
  83. 83.
    Boeckh M, Bowden RA, Goodrich JM et al. (1992) Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 80:1358–1364PubMedGoogle Scholar
  84. 84.
    Einsele H, Ehninger G, Hebart H et al. (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and the side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815–2820PubMedGoogle Scholar
  85. 85.
    Goodrich JM, Mori M, Gleaves CA (1991) Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601–1607PubMedCrossRefGoogle Scholar
  86. 86.
    American College of Chest Physicians/Society of Critical care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864CrossRefGoogle Scholar
  87. 87.
    Meyer P, Adam D, Hiddemann W et al. (1992) Interventionstherapie von Infektionen und Fieber unklarer Genese bei neutropenischen Patienten mit malignen hämatologischen Grunderkrankungen. Z Antimikrob Chemother 10:1–28Google Scholar
  88. 88.
    Merck&Co, INC Whitehouse station, NJ 0889 U (2001) CANCIDAS 7 (caspofungin acetate) for injection, 9344300Google Scholar
  89. 89.
    Chandrasekar PH, Manavathu E (2001) Voriconazole: a second generation triazole. Drugs Today 37:135–148PubMedGoogle Scholar
  90. 90.
    Link H, Blumenstengel K, Bohme A et al. (1999) Antimikrobielle Therapie von unerklärtem Fieber bei Neutropenie. Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr 124(Suppl 1):S3–S8PubMedGoogle Scholar
  91. 91.
    Link H, Blumenstengel K, Böhme A et al. (2001) Antimikrobielle Therapie von unerklärtem Fieber bei NeutropenieStandardempfehlungen der Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO), Arbeitsgruppe Interventionstherapie bei unerklärtem FieberArbeitsgemeinschaft Supportivtherapie (AK-SUPPO) der Deutschen Krebsgesellschaft (DKG) 2. aktualisierte Fassung Januar 2001. http://www.DGHO-Infektionen.de
  92. 92.
    Maschmeyer G, Hertenstein B, Glass B, Schiel X (1999) Interventional antimicrobial therapy for febrile complications after high-dose chemotherapy and autologous stem cell transplantation. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology. Dtsch Med Wochenschr 124(Suppl 1):S9-13Google Scholar
  93. 93.
    Maschmeyer G, Beinert T, Buchheidt D et al. (1999) Diagnosis and therapy of lung infiltrates in febrile neutropenic patients. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology. Dtsch Med Wochenschr 124(Suppl 1):S18-S23Google Scholar
  94. 94.
    Ostermann H, Derigs HG, Heussel G et al. (1999) Sepsis in Neutropenie Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologieder Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr 124(Suppl 1): S14–S17PubMedGoogle Scholar
  95. 95.
    Fätkenheuer G, Buchheidt D, Fuhr HG et al. (2001) Venenkatheter-as-soziierte Infektionen bei Patienten mit Neutropenie. Dtsch Med Wochenschr 126/4:89–95PubMedCrossRefGoogle Scholar
  96. 96.
    Buchheidt D, Böhme A, Comely O et al. (2001) Dokumentierte Infektionen bei Neutropenie — Empfehlungen zu Diagnostik und Therapie, Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie — Fachgruppe der Deutschen Gesellschaft für Hämatologieund Onkologie. Dtsch Med Wochenschr 126:1085–1090PubMedCrossRefGoogle Scholar
  97. 97.
    Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y (1994) Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. Bone Marrow Transplant 14:919–924PubMedGoogle Scholar
  98. 98.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRefGoogle Scholar
  99. Alter MJ, Mast EE (1994) The epidemiology of viral hepatitis in the United States. Gastroenterol Clin N Am 23:437–55Google Scholar
  100. Backmund M, Eichenlaub D (1999) Drogenendokarditis. In: Zerkowski H-R, Baumann G (Hrsg) HerzAkutmedizin. Steinkopff, Darmstadt, S 491–496Google Scholar
  101. Backmund M, Eichenlaub D (1999) Drogennotfälle. In: Zerkowski H-R, Baumann G (Hrsg) HerzAkutmedizin. Steinkopff, Darmstadt, S 497–504Google Scholar
  102. Backmund M, Stephan E (1999) Sepsis. In: Backmund M (Hrsg) Suchttherapie. Ecomed, Landsberg/Lech, S XIII-1.4.4Google Scholar
  103. Backmund M, Stephan E (1999) Virushepatitiden. In: Backmund M (Hrsg) Suchttherapie. Ecomed, Landsberg/Lech, S Xlll,-1.4.1Google Scholar
  104. Backmund M, Stephan E (1999) Tuberkulose. In: Backmund M (Hrsg) Suchttherapie. Ecomed, Landsberg/Lech, S Xlll,-1.4.6Google Scholar
  105. Backmund M (2000) Pneumonie. In: Backmund M (Hrsg) Suchttherapie. EcomedLandsberg/Lech, S Xlll,-1.4.3Google Scholar
  106. Bocshini A, Smacchia C, Di Fine M et al. (1996) Community-aquired pneumonia in a cohort of former injection drug users with and without human immunodeficency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis 23:107–113CrossRefGoogle Scholar
  107. Brodt HR, Helm EB, Kamps B (2000) AIDS 2000. Steinhäuser, WuppertalGoogle Scholar
  108. Crofts N, Cooper G, Stewart T et al. (1997) Exposure to hepatitis A virus among blood donors, injecting drug users and prison entrants in Victoria. K J Viral Hepat 4:333–338CrossRefGoogle Scholar
  109. Dressier FA, Roberts WC (1989) Infective endocarditis in opiate addicts: Analysis of 80 cases studied at necropsy. Am J Cardiol 63:1240CrossRefGoogle Scholar
  110. Friedland HJ, Selwyn PA (1995) Infektionen bei Anwendung intravenöser Drogen. In: Schmailzl KJG (Hrsg) Harrison’s Innere Medizin. Blackwell, Berlin Wien, S 670–676Google Scholar
  111. Henriksen BM, Albrektsen SB, Simper LB, Gutschik G (1994) Soft tissue infections from drug abuse. A clinical and microbiological review of 145 cases. Acta Orthop Scand 65:625–628PubMedCrossRefGoogle Scholar
  112. Huber-Schneider C, Gubler J, Knoblauch M (1994) Endokarditis durch Corynebacterium diphteriae bei Kontakt mit intravenösen Drogen: Bericht über 5 Fälle. Schweiz Med Wochenschr 124:2173–2180PubMedGoogle Scholar
  113. Karchmer AW (1997) Infective endocarditis. In: Braunwald E (Hrsg) Heart disease. A textbook of cardiovascular medcine, vol 2. Saunders, London, pp 1078–1104Google Scholar
  114. Kaye D (1995) Infektiöse Endokarditis. In: Schmailzl KJG (Hrsg) Harrison’s Innere Medizin. Blackwell Wiss., Berlin Wien, S 619–625Google Scholar
  115. Levine DP, Sobel JD. Infections in intravenous drug abusers (1995) In: Mandell GL, Bennett JE, Dolin R (eds). Churchill Livingstone, New York Edinburgh London, pp 2696–2708Google Scholar
  116. Peterson R (1996) Rauschgiftlage 1995. In: Deutsche Hauptstelle gegen die Suchtgefahren (Hrsg) Jahrbucht Sucht 1997. Neuland, Geesthacht, S 55–72Google Scholar
  117. Rieger-Nddakowera G, Körte W, Nielsen A, Ruschmeyer J, Spors P, Fell G (1994) Infektionsepidemiologie — Analyse der Zunahme der infektiösen Hepatitis in Hamburg. Gesundheitswesen 56:132–136Google Scholar
  118. Sande MA, Lee BL, Mills J et al. (1992) Endocarditis in intravenous drug users. In: Kaye D (ed) Infective endocarditis. Raven, New York, p 345Google Scholar
  119. Scheidegger C, Zimmerli W (1989) Infectious complications in drug addicts: seven-year review of 269 hospitalized narcotics abuser in Switzerland. Rev Infect Dis 11:486–493PubMedCrossRefGoogle Scholar
  120. Summannen PH, Talan DA, Strong C et al. (1995) Bacteriology of skin and soft-tissue infections: Comparsion of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis 20(Suppl 2): 279–282CrossRefGoogle Scholar
  121. Tennant F, Moll D (1995) Seroprevalence of hepatitis A, B, C, and D markers and liver function abnormalities in intravenous heroin addicts. J Addict Dis 14:35–49PubMedCrossRefGoogle Scholar
  122. Vento S, Garofano T, Renzini C et al. (1998) Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 338:286–90PubMedCrossRefGoogle Scholar
  123. Wächtler M, Meyer K, Maier S, Höcherl EFJ, Eichenlaub D, Backmund M (2000) Polytoxikomane Patientin mit rezidivierender offener Gangrän und chronischer Osteomyelitis des rechten Unterarms. Suchtmedizin 1:3–6Google Scholar
  124. Wilson WR, Karchmer AW, Dajani AS et al. (1995) Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 274:1706–1713PubMedCrossRefGoogle Scholar
  125. 1.
    Nashan B, Schlitt HJ, Schwinzer R et al. (1996) Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 61:546–554PubMedCrossRefGoogle Scholar
  126. 2.
    Kuse ER, Langefeld I, Jaeger K, Kulpmann WR (2000) Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med 28/2:555–559PubMedCrossRefGoogle Scholar
  127. 3.
    Humphreys H, Willatts S, Vincent JL (2000) Infection in the immunnosuppressed patients. In: Humphreys H, Willatts S, Vincent JL (eds) Intensive care infection. Saunders, London Edinurgh-New York, pp 193–206Google Scholar
  128. 4.
    Petri WA (1994) Infection in heart transplant recipients. Clin Infect Dis 18:141–148PubMedCrossRefGoogle Scholar
  129. 5.
    Winston DJ, Emmanouilides C, Busuttil RW (1995) Infection in liver transplant recipients. Clin Infect Dis 21:1077–1091PubMedCrossRefGoogle Scholar
  130. 6.
    Sarmento A, Freitas F, Tavares AP, Machado D (2000) Organ donor viral screening and its implications in transplantation; an overview. Transplant Proc 32:2571–2576PubMedCrossRefGoogle Scholar
  131. 7.
    Council of Europe (1997) State of the art report on serological screening methods for the most relevant microbiological diseases of organ and tissue donors. http://www.social.coe.int./en/qoflife/publi/microbio.htm
  132. 8.
    Wissenschaftlicher Beirat der Bundesärztekammer (1999) Stellungnahme des Wissenschaftlichen Beirats der Bundesärztekammer zur Xenotransplantation. Dtsch Ärztebl 96:B1541–B1547Google Scholar
  133. 9.
    Wissenschaftlicher Beirat der Bundesärztekammer (2001) Richtlinien zum Führen einer Knochenbank. Dtsch Ärztebl 98:C807–C812Google Scholar
  134. 10.
    Wade JJ, Rolando N, Hayllar K et al. (1995) Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 21/5:1328–1336PubMedCrossRefGoogle Scholar
  135. 11.
    Tollemar J, Hockerstedt K, Ericzon BG et al. (1995) Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 59/1:45–50PubMedCrossRefGoogle Scholar
  136. 12.
    Liebau P, Kuse E, Winkler M et al. (1996) Management of herpes simplex virus type 1 pneumonia following liver transplantation. Infection;24:130–135PubMedCrossRefGoogle Scholar
  137. 13.
    Krüger M (2000) European hepatitis B immunoglobulin trials: prevention of recurrent hepatitis B after liver transplantation. Clin Transplant 14(Suppl 2): 14–19PubMedGoogle Scholar
  138. 14.
    Klempnauer J, Manns MP (2000) Hepatitis und Lebertransplantation. Chirurg 71/4:404–491PubMedCrossRefGoogle Scholar
  139. 15.
    Schlitt HJ, Nashan B, Ringe B et al. (1991) Differentiation of liver graft dysfunction by transplant aspiration cytology. Transplantation 51/4:786–793PubMedCrossRefGoogle Scholar
  140. 16.
    Couchoud C (2000) Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Database Syst Rev: CD001320Google Scholar
  141. 17.
    Vogel JU, Scholz M, Cinatl J (1997) Treatment of cytomegalovirus diseases. Intervirology 40/5–6:357–367PubMedCrossRefGoogle Scholar
  142. 18.
    De Maria R (1996) Prognostic determinats of six-month morbidity and mortality in heart transplant recipients. The Italian Study Group on Infection in Heart Transplantation. J Heart Lung Transplant 15:124–135PubMedGoogle Scholar
  143. 19.
    Trancassini M, Mosca G, Margiotta MC et al. (2001) Microbiologic investigation on patients with cystic fibrosis subjected to bilateral lung transplantation. Transplantation 72/9:1575–1577PubMedCrossRefGoogle Scholar
  144. 20.
    Tolkoff-Rubin NE, Rubin RH (2000) Recent advances in the diagnosis and management of infection in the organ transplant recipient. Semin Nephrol 20:148–163PubMedGoogle Scholar
  145. 21.
    Padovan CS, Sostak P, Straube A (2000) Neurologische Komplikationen nach Organtransplantation. Nervenarzt 71:249–258PubMedCrossRefGoogle Scholar
  146. 22.
    Tanphaichitr NT, Brennan DC (2000) Infectious complications in renal transplant recipients. Adv Ren Replace Ther 7:131–146PubMedGoogle Scholar
  147. 23.
    Shirali GS, Ni J, Chinnock RE, Johnston JK et al. (2001) Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 344:1498–1503PubMedCrossRefGoogle Scholar
  148. 24.
    Avery RK (2001) Viral triggers of cardiac-allograft dysfunction. N Engl J Med 344:1545–1547PubMedCrossRefGoogle Scholar
  149. 25.
    Knisely BL, Mastey LA, Collins J, Kuhlman JE (1999) Imaging of cardiac transplantation complications. Radiographics 19:321–339PubMedGoogle Scholar
  150. 26.
    Savitsky EA, Votey SR, Mebust DP et al. (2000) A descriptive analysis of 290 liver transplant patient visits to an emergency department. Acad Emerg Med 7:898–905PubMedCrossRefGoogle Scholar
  151. 27.
    De Meo DL, Ginns LC (2001) Lung transplantation at the turn of the century. Annu Rev Med 52:185–201CrossRefGoogle Scholar
  152. 28.
    Williamson EC, Millar MR, Steward CG et al. (1999) Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 104:560–568PubMedCrossRefGoogle Scholar
  153. 29.
    Morrice GD (1998) CJD was not diagnosed until eight months after organ donor’s death. BMJ 316:630PubMedGoogle Scholar
  154. 30.
    Brown P (1998) Transmission of spongiform encephalopathy through biological products. Dev Biol Stand 93:73–78PubMedGoogle Scholar
  155. 31.
    Nichols WG, Boeckh M (2000) Recent advances in the therapy and prevention of CMV infections. J Clin Virol 16:25–40PubMedCrossRefGoogle Scholar
  156. 32.
    Verschuuren EA, Stevens S, Hanekamp BB et al. (2001) Patients at risk for post-transplant lymphoproliferative disease can be identified in the first months after lung transplantation by quantitative-competitive-EBV-PCR. J Heart Lung Transplant 20:199Google Scholar
  157. 33.
    Koh BY, Rosenthal P, Medeiros LJ et al. (2001) Posttransplantation lymphoproliferative disorders in pediatric patients undergoing liver transplantation. Arch Pathol Lab Med 125:337–343PubMedGoogle Scholar
  158. 34.
    Fall AJ, Aitchison JD, Krause A et al. (2000) Donor organ transmission of varicella zoster due to cardiac transplantation. Transplantation 70:211–213PubMedGoogle Scholar
  159. 35.
    Tong MJ, Terrault NA, Klintmalm G (2000) Hepatitis B transplantation: special conditions. Semin Liver Dis 20 Suppl 1:25–28Google Scholar
  160. 36.
    Keeffe EB (2000) End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B. J Med Virol 61:403–408PubMedCrossRefGoogle Scholar
  161. 37.
    Freiman JS, McCaughan GW (2000) Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings. J Gastroenterol Hepatol 15:227–229PubMedCrossRefGoogle Scholar
  162. 38.
    Samuel D, Feray C (2000) Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat 7:87–92PubMedCrossRefGoogle Scholar
  163. 39.
    Daneshpouy M, Socie G, Clavel C et al. (2001) Human papillomavirus infection and anogenital condyloma in bone marrow transplant recipients. Transplantation 71:167–169PubMedCrossRefGoogle Scholar
  164. 40.
    Lui SL, Luk WK, Cheung CY et al. (2001) Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation 71:59–64PubMedCrossRefGoogle Scholar
  165. 41.
    Zolnourian ZR, Curran MD, Rima BK et al. (2000) Parvovirus B19 in kidney transplant patients. Transplantation 69:2198–2202PubMedCrossRefGoogle Scholar
  166. 42.
    Krinzman S, Basgoz N, Kradin R et al. (1998) Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant 17:202–210PubMedGoogle Scholar
  167. 43.
    Avery RK (2001) Viral triggers of cardiac-allograft dysfunction. N Engl J Med 344:1545–1547PubMedCrossRefGoogle Scholar
  168. 44.
    Burket JS, Chenoweth CE, Meyer TL, Barg NL (1999) Donor-to-recipient transmission of bacteria as an unusual cause of mediastinitis in a heart transplant recipient. Infect Control Hosp Epidemiol 20:132–133PubMedCrossRefGoogle Scholar
  169. 45.
    Freeman RB, Giatras I, Falagas ME et al. (1999) Outcome of transplantation of organs procured from bacteremic donors. Transplantation 68:1107–1111PubMedCrossRefGoogle Scholar
  170. 46.
    Girmenia C, lori AP, Bernasconi S et al. (2000) Listeriosis in recipients of allogeneic bone marrow transplants from unrelated donors. Eur J Clin Microbiol Infect Dis 19:711–714PubMedCrossRefGoogle Scholar
  171. 47.
    Ernst A, Gordon FD, Hayek J, Silvestri RC, Koziel H (1998) Lung abcess complicating Legionella micdadei pneumonia in an adult liver transplant recipient: case report and review. Transplantation 65:130–134PubMedCrossRefGoogle Scholar
  172. 48.
    Chow JW, Yu VL (1998) Legionella: a major opportunistic pathogen in transplant recipients. Semin Respir Infect 13:132–139PubMedGoogle Scholar
  173. 49.
    Mathys W, Deng MC, Meyer J, Junge-Mathys E (1999) Fatal nosocomial Legionnaires’ disease after heart transplantation: clinical course, epidemiology and prevention strategies for the highly immunocompromized host. J Hosp Infect 43:242–246PubMedCrossRefGoogle Scholar
  174. 50.
    Dowdy L, Ramgopal M, Hoffman T et al. (2001) Genitourinary tuberculosis after renal transplantation: report of 3 cases and review. Clin Infect Dis 32:662–666PubMedCrossRefGoogle Scholar
  175. 51.
    Gaviria JM, Garcia PJ, Garrido SM, Corey L, Boeckh M (2000) Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 6:361–369PubMedCrossRefGoogle Scholar
  176. 52.
    Wilkin A, Feinberg J (2000) Prophylaxis against fungal infections and cytomegalovirus disease after bone marrow transplantation. Oncology (Huntingt) 14:1701–1708Google Scholar
  177. 53.
    Hoffman HL, Ernst EJ, Klepser ME (2000) Novel triazole antifungal agents. Expert Opin Investig Drugs 9:593–605PubMedCrossRefGoogle Scholar
  178. 54.
    Ho PL, Yuen KY (2000) Aspergillosis in bone marrow transplant recipients. Crit Rev Oncol Hematol 34:55–69PubMedCrossRefGoogle Scholar
  179. 55.
    Patterson TF, Kirkpatrick WR, White M et al. (2000) Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore) 79:250–260CrossRefGoogle Scholar
  180. 56.
    Bosi A, Zazzi M, Amantini A, Cellerini M, Vannucchi AM, De Milito A, Guidi S, Saccardi R, Lombardini L, Laszlo D, Rossi FP (1998) Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. Bone Marrow Transplant 22:285–288PubMedCrossRefGoogle Scholar
  181. 57.
    Lau YL, Peiris M, Chan GC, Chan AC, Chiu D, Ha SY (1998) Primary human herpes virus 6 infection transmitted from donor to recipient through bone marrow infusion. Bone Marrow Transplant 21:1063–1066PubMedCrossRefGoogle Scholar
  182. 58.
    Yoshikawa T, Suzuki K, Ihira M, Furukawa H, Suga S, Asano Y, Kojima S, Kato K, Matsuyama T (1998) Prediction of human herpesvirus 6 infection after allogeneic bone marrow transplantation. Blood 92:2597–2599PubMedGoogle Scholar
  183. 59.
    Griffiths PD, Clark DA, Emery VC (2000) Betaherpesviruses in transplant recipients. J Antimicrob Chemother 45 Suppl T3:29–34CrossRefGoogle Scholar
  184. 60.
    Luppi M, Barozzi P, Santagostino G, Trovato R, Schulz TF, Marasca R, Bottalico D, Bignardi L, Torelli G (2000) Molecular evidence of organrelated transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 96:3279–3281PubMedGoogle Scholar
  185. 61.
    Simonds RJ, Holmberg SD, Hurwitz RL, Coleman TR, Bottenfield S, Conley LJ, Kohlenberg SH, Castro KG, Dahan BA, Schable CA (1992) Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 326:726–732PubMedCrossRefGoogle Scholar
  186. 62.
    Nickeleit V, Klimkait T, Binet IF, Dalquen P, Del Z, V, Thiel G, Mihatsch MJ, Hirsch HH (2000) Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 342:1309–1315PubMedCrossRefGoogle Scholar
  187. 63.
    Shah KV (2000) Human polyomavirus BKVand renal disease. Nephrol Dial Transplant 15:754–755PubMedCrossRefGoogle Scholar
  188. 64.
    Caspari G (Gerlich WH) (2003) Durch Blut übertragbare Infektionskrankheiten. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Grundlagen — Therapie-Methodik, 3. Aufl. Springer, Berlin Heidelberg New York Tokio (im Druck)Google Scholar
  189. 65.
    Palau LA, Pankey GA (1997) Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: possible Strongyloides stercoralis transmission by kidney transplant. Am J Trop Med Hyg 57:413–415PubMedGoogle Scholar
  190. 66.
    Munir A, Zaman M, Eltorky M (2000) Toxoplasma gondii pneumonia in a pancreas transplant patient. South Med J 93:614–617PubMedGoogle Scholar
  191. 67.
    Williams HA, Roberts J, Kachur SP, Barber AM, Barat LM, Bioland PB, Ruebush TK, Wolfe EB (1999) Malaria surveillance-United States, 1995. Mor Mortal Weekly Rep CDC Surveill Summ 48:1–23Google Scholar
  192. 68.
    Fischer L, Sterneck M, Claus M, Costard-Jackie A, Fleischer B, Herbst H, Rogiers X, Broelsch CE (1999) Transmission of malaria tertiana by multi-organ donation. Clin Transplant 13:491–495PubMedCrossRefGoogle Scholar
  193. 69.
    Hernandez-Perez J, Yebra-Bango M, Jimenez-Martinez E, Sanz-Moreno C, Cuervas-Mons V, Alonso PL, Ramos-Martinez A, Fernandez-Fernandez J (1999) Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review. Clin Infect Dis 29:918–921PubMedCrossRefGoogle Scholar
  194. 70.
    Michaels MG, Jenkins FJ, St George K, Nalesnik MA, Starzl TE, Rinaldo CR, Jr (2001) Detection of infectious baboon cytomegalovirus after baboon-to-human liver xenotransplantation. J Virol 75:2825–2828PubMedCrossRefGoogle Scholar
  195. 71.
    Kedda MA, Kramvis A, Kew MC, Lecatsas G, Paterson AC, Aspinall S, Stark JH, De Klerk WA, Gridelli B (2000) Susceptibility of chacma baboons (Papio ursinus orientalis) to infection by hepatitis B virus. Transplantation 69:1429–1434PubMedCrossRefGoogle Scholar
  196. 72.
    Allan JS (1998) The risk of using baboons as transplant donors. Exogenous and endogenous viruses. Ann N Y Acad Sci 862:87–99PubMedCrossRefGoogle Scholar
  197. 73.
    Allan JS, Broussard SR, Michaels MG, Starzl TE, Leighton KL, Whitehead EM, Comuzzie AG, Lanford RE, Leland MM, Switzer WM, Heneine W (1998) Amplification of simian retroviral sequences from human recipients of baboon liver transplants. AIDS Res Hum Retroviruses 14:821–824PubMedCrossRefGoogle Scholar
  198. 74.
    Denner J (1998) Immunosuppression by retroviruses: implications for xenotransplantation. Ann N Y Acad Sci 862:75–86PubMedCrossRefGoogle Scholar
  199. 75.
    Groth CG, Tibell A, Wennberg L, Bennet W, Lundgren T, Rydgard KJ, Lundin S, Lindeborg E, Korsgren O (2000) Clinical aspects and perspectives in islet xenotransplantation. J Hepatobiliary Pancreat Surg 7:364–369PubMedCrossRefGoogle Scholar
  200. 76.
    Yoo D, Giulivi A (2000) Xenotransplantation and the potential risk of xenogeneic transmission of porcine viruses. Can J Vet Res 64:193–203PubMedGoogle Scholar
  201. 1.
    Link H, Kolb HJ, Ebell W et al. (1997) Die Transplantation hämatopoetischer Stammzellen Teil I: Definitionen, prinzipielle Anwendungsmöglichkeiten, Komplikationen. Med Klin 92/8:480–491CrossRefGoogle Scholar
  202. 2.
    Link H, Kolb HJ, Ebell W et al. (1997) Die Transplantation hämatopoetischer Stammzellen Teil II: Indikationen zur Transplantation von hämatopoetischen Stammzellen nach myeloablativer Therapie. Med Klin 92:534–545CrossRefGoogle Scholar
  203. 3.
    Thomas ED (1995) Bone marrow transplantation from bench to bedside. Ann N Y Acad Sci 770:34–41PubMedCrossRefGoogle Scholar
  204. 4.
    Kurtzberg J, Laughlin M, Graham ML et al. (1996) Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335/3:157–166PubMedCrossRefGoogle Scholar
  205. 5.
    Silberstein LE, Jefferies LC (1996) Placental-blood banking — a new frontier in transfusion medicine. N Engl J Med 335/3:199–201PubMedCrossRefGoogle Scholar
  206. 6.
    Ferrant A, Doyen C, Delannoy A et al. (1995) Karyotype in acute myeloblastic leukemia: Prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplant 15/5:685–690PubMedGoogle Scholar
  207. 7.
    Link H, Arseniev L, Bähre O et al. (1995) Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood 86/7:2500–2508PubMedGoogle Scholar
  208. 8.
    McSweeney PA, Niederwieser D, Shizuru JA et al. (2001) Hematopoietic cell transplantation in older patients with hematologie malignancies: replacing high-dose cytotoxic therapy with graft-vs.-tumor effects. Blood 97/11:3390–3400PubMedCrossRefGoogle Scholar
  209. 9.
    Kernan NA, Dupont B (1996) Minor histocompatibility antigens and marrow transplantation. N Engl J Med 334/5:323–324PubMedCrossRefGoogle Scholar
  210. 10.
    van der Meer JWM, Guiot HFL, van den Broek PJ, van Furth R (1984) Infections in bone marrow transplant recipients. Semin Hematol 21:123–140PubMedGoogle Scholar
  211. 11.
    Phillips GL (1988) The management of infections. In: Deeg HJ, Klingemann HG, Phillips GL (eds) A guide to bone marrow transplantation. Springer, Berlin Heidelberg New York Tokyo, pp 107–113Google Scholar
  212. 12.
    Meyers JD (1986) Infection in bone marrow transplant recipients. Am J Med 81(Suppl 1 A):27–38PubMedCrossRefGoogle Scholar
  213. 13.
    Weiner RS, Bortin MM, Gale RP et al. (1986) Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 104:168–175PubMedGoogle Scholar
  214. 14.
    Miller W, Flynn P, McCullough J et al. (1986) Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 67:1162–1167PubMedGoogle Scholar
  215. 15.
    Winston DJ, Ho WG, Champlin RE, Gale RP (1984) Infectious complications of bone marrow transplantation. Exp Hematol 12:205–215PubMedGoogle Scholar
  216. 16.
    Witherspoon RP, Storb R, Ochs HD et al. (1981) Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-vs.-host disease, and antithymocyte globulin treatment. Blood 58:360–368PubMedGoogle Scholar
  217. 17.
    Cordonnier C, Engelhard D, Ljungman P et al. (2001) Definitions of Infectious Diseases and Complications after Stem Cell Transplant A proposal from the Infectious Diseases Working Party 1 Nov 2001 Version 1. 1-11-2001. http://www.ebmt.org/EBMTNEW/5WorkingParties/IDWP/wparties-id6.htm
  218. 18.
    Böhme A, Karthaus M, Einsele H et al. (1999) Diagnostik systemischer Pilzinfektionen in der Hämatologie-Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr 124(Suppl 1): S24–S30PubMedGoogle Scholar
  219. 19.
    Buchheidt D, Böhme A, Comely O et al. (2001) Dokumentierte Infektionen bei Neutropenie — Empfehlungen zu Diagnostik und Therapie, Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie — Fachgruppe der Deutschen Gesellschaft für Hämatologieund Onkologie. Dtsch Med Wochenschr 126:1085–1090PubMedCrossRefGoogle Scholar
  220. 20.
    Einsele H, Bertz H, Beyer J et al. (2001) Epidemiologie und interventionelle Therapiestrategien infektiöser Komplikationen nach allogener Stammzelltransplantation. Dtsch Med Wochenschr 126/45:1278–1284PubMedCrossRefGoogle Scholar
  221. 21.
    Fätkenheuer G, Buchheidt D, Fuhr HG et al. (2001) Venenkatheterassoziierte Infektionen bei Patienten mit Neutropenie. Dtsch Med Wochenschr 126/4:89–95PubMedCrossRefGoogle Scholar
  222. 22.
    Link H, Blumenstengel K, Böhme A et al. (1999) Antimikrobielle Therapie von unerklärtem Fieber bei Neutropenie Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr 124(Suppl 1): S3–S8PubMedGoogle Scholar
  223. 23.
    Maschmeyer G, Hertenstein B, Glass B, Schiel X (1999) Interventionelle antimikrobielle Therapie febriler Komplikationen nach Hochdosistherapie und autologer Stammzelltransplantation. Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr 124(Suppl 1):S9-13Google Scholar
  224. 24.
    Maschmeyer G, Beinert T, Buchheidt D, Einsele H, Holler E (1999) Diagnostik und Therapie von Lungeninfiltraten bei febrilen neutropenischen Patienten — Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr 124(Suppl 1): S18–S23PubMedGoogle Scholar
  225. 25.
    Ostermann H, Derigs HG, Heussel G et al. (1999) Sepsis in Neutropenie Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr 124(SuppM):S14–S17PubMedGoogle Scholar
  226. 26.
    Link H, Blumenstengel K, Böhme A et al. (2001) Antimikrobielle Therapie von unerklärtem Fieber bei Neutropenie Standardempfehlungen der Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO. der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO), Arbeitsgruppe Interventionstherapie bei unerklärtem Fieber Arbeitsgemeinschaft Supportivtherapie (AK-SUPPO der Deutschen Krebsgesellschaft (DKG, 2. aktualisierte Fassung Januar 2001. http://www.DGHO-lnfektionen.de
  227. 27.
    Wald A, Leisenring W, van Burik JA, Bowden RA (1997) Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175:1459–1466PubMedCrossRefGoogle Scholar
  228. 28.
    Yu VL, Muder RR, Poorsattar A (1986) Significance of isolation of aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med 81:249–254PubMedCrossRefGoogle Scholar
  229. 29.
    Walsh TJ, Finberg RW, Arndt C et al. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340/10:764–771PubMedCrossRefGoogle Scholar
  230. 30.
    Chandrasekar PH, Manavathu E (2001) Voriconazole: a second generation triazole. Drugs Today 37:135–148PubMedGoogle Scholar
  231. 31.
    Boogaerts M, Winston DJ, Bow EJ et al. (2001) Intravenous and oral itraconazole vs. intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenie patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135/6:412–422PubMedGoogle Scholar
  232. 32.
    Rubin RH (1991) Preemptive therapy in immunocompromised hosts. N Engl J Med 324/15:1057–1059PubMedCrossRefGoogle Scholar
  233. 33.
    Caillot D, Casasnovas O, Bernard A et al. (1997) Improved management of invasive pulmonary aspergillosis in neutropenie patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15/1:139–147PubMedGoogle Scholar
  234. 34.
    Hebart H, Offler J, Meisner C et al. (2000) Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 181/5:1713–1719PubMedCrossRefGoogle Scholar
  235. 35.
    Buchheidt D, Baust C, Skladny H et al. (2001) Detection of aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. Clin Infect Dis 33/4:428–435PubMedCrossRefGoogle Scholar
  236. 36.
    Ljungman P, Ward KN, Crooks BN et al. (2001) Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 28:479–484PubMedCrossRefGoogle Scholar
  237. 37.
    Ljungman P, Ellis MN, Hackman RC, Shepp DH, Meyers JD (1990) Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 162:244–248PubMedCrossRefGoogle Scholar
  238. 38.
    Darville JM, Ley BE, Roome AP, Foot AB (1998) Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population. Bone Marrow Transplant 22/6:587–589PubMedCrossRefGoogle Scholar
  239. 39.
    Reusser P, Cordonnier C, Einsele H et al. (1996) European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 17:813–817PubMedGoogle Scholar
  240. 40.
    Locksley RM, Flournoy N et al. (1985) Infection with varicella-zoster virus after marrow transplantation. J Infec Dis 152:1172–1181CrossRefGoogle Scholar
  241. 41.
    Bilgrami S, Chakraborty NG, Rodriguez-Pinero F et al. (1999) Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue. Bone Marrow Transplant 23:469–474PubMedCrossRefGoogle Scholar
  242. 42.
    Wacker P, Hartmann O, Benhamou E, Salloum E, Lemerle J (1989) Varicella-zoster virus infections after autologous bone marrow transplantation in children. Bone Marrow Transplant 4:191–194PubMedGoogle Scholar
  243. 43.
    Hersman J, Meyers JD, Thomas ED, Buckner CD, Clift RA (1982) The effect of granulocyte transfusion on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med 96:149–152PubMedGoogle Scholar
  244. 44.
    Grundy (Chalmer._JE, Mackenzie JS, Stanley NF (1981) Influence of H-2 and Non-H-2 genes on resistance to murine cytomegalovirus infection. Infect Immunity 32:277–286Google Scholar
  245. 45.
    Collaborative DHPG Treatment Study Group (1986) Treatment of serious cytomegalovirus infection with 9-(1,3-dihydrox-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 314:801–805CrossRefGoogle Scholar
  246. 46.
    Neiman PE, Meyers J, Medeiros E, McDougall JK, Thomas ED (1980) Interstitial pneumonia following marrow transplantation for leukemia and aplastic anemia. UCLA Symposia 17:75–81Google Scholar
  247. 47.
    Jordan MC (1983) Latent infection and the elusive cytomegalovirus. Rev Infect Dis 5:205–215PubMedCrossRefGoogle Scholar
  248. 48.
    Rice GPA, Schrier RD, Oldstone MBA (1984) Cytomegalovirus infects human lymphocytes: virus expression is restricted to immediateearly gene products. Proc Natl Acad Sci USA 81:6134–6138PubMedCrossRefGoogle Scholar
  249. 49.
    Braun RW, Reiser HC (1986) Replication of human cytomegalovirus in human peripheral blood T cells. J Virol 60:29–36PubMedGoogle Scholar
  250. 50.
    Saltzman RL, Quirk MR, Jordan MC (1988) Disseminated cytomegalovirus infection. Molecular analysis of virus and leukocyte interactions in viremia. J Clin Invest 81:75–81PubMedCrossRefGoogle Scholar
  251. 51.
    Einhorn L, Ost A (1984) Cytomegalovirus infection of human blood cells. J Infec Dis 149:207–214CrossRefGoogle Scholar
  252. 52.
    Schrier RD, Nelson JA, Oldstone MBA (1985) Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science 230:1048–1050PubMedCrossRefGoogle Scholar
  253. 53.
    Link H, Battmer K, Stumme C (1993) Cytomegalovirus infection in leukocytes after bone marrow transplantation demonstrated by mRNA in situ hybridization. Br J Haematol 85:573–577PubMedCrossRefGoogle Scholar
  254. 54.
    Link H, Battmer K, Kleine HD (1992) Detection of cytomegalovirusinfected cells by flow cytometry and fluorescence in suspension hybridization (FLASH, using DNA probes biotin-labeled by polymerase chain reaction. J Med Virol 37:143–148PubMedCrossRefGoogle Scholar
  255. 55.
    Vilmer E, Mazeron MC, Rabian C et al. (1985) Clinical significance of cytomegalovirus viremia in bone marrow transplantation. Transplantation 40:30–35PubMedCrossRefGoogle Scholar
  256. 56.
    Meyers JD, Flournoy N, Thomas ED (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153:478–488PubMedCrossRefGoogle Scholar
  257. 57.
    Bale JF, O’Neil ME, Giller R, Perlman S, Koszinowski U (1987) Murine cytomegalovirus genomic material in marrow cells: relation to altered leukocyte counts during sublethal infection of mice. J Infec Dis 155:207–212CrossRefGoogle Scholar
  258. 58.
    Mutter W, Reddehase MJ, Busch FW, Bühring HJ, Koszinowski UH (1988) Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host. J Exp Med 167:1645–1658PubMedCrossRefGoogle Scholar
  259. 59.
    Reiser H, Kühn J, Doerr HW et al. (1986) Human cytomegalovirus replicates in primary human bone marrow cells. J Gen Virol 67:2595–2604PubMedCrossRefGoogle Scholar
  260. 60.
    Ljungman P, Engelhard D, Link H et al. (1992) Treatment of interstital pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European bone marrow transplant group. Clin Inf Dis 14:831–835CrossRefGoogle Scholar
  261. 61.
    Ljungman P, Biron P, Bosi A et al. (1994) Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Bone Marrow Transplant 13:209–212PubMedGoogle Scholar
  262. 62.
    Ljungman P, Cordonnier C, Einsele H et al. (1996) Current practices for management of CMV infections in allogeneic BMT recipients in EBMT centers. Bone Marrow Transplant 17 (Suppl 1):S11–S11Google Scholar
  263. 63.
    Boeckh M (1999) Management of cytomegalovirus infections in blood and marrow transplant recipients. Adv Exp Med Biol 458:89–109PubMedGoogle Scholar
  264. 64.
    Ljungman P, Deliliers GL, Platzbecker U et al. (2001) Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 97/2:388–392PubMedCrossRefGoogle Scholar
  265. 65.
    Boeckh M (1999) Successful modification of a pp65 antigenemiabased early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 93/5:1781–1782PubMedGoogle Scholar
  266. 66.
    Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H, Ljungman P (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99:1159–1164PubMedCrossRefGoogle Scholar
  267. 67.
    Goodrich JM, Bowden RA, Fisher L et al. (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178PubMedGoogle Scholar
  268. 68.
    Boeckh M (1996) Cytom egalovirus pp65 antigenemia-guided early treatment with ganciclovir vs. ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88/10:4063–4071PubMedGoogle Scholar
  269. 69.
    Hebart H, Brugger W, Grigoleit U et al. (2001) Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 97/7:2183–2185PubMedCrossRefGoogle Scholar
  270. 70.
    Nichols WG, Corey L, Gooley T et al. (2001) Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 97/4:867–874PubMedCrossRefGoogle Scholar
  271. 71.
    Walter E, Greenberg PD, Gilbert MJ et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333/16:1038–1044PubMedCrossRefGoogle Scholar
  272. 72.
    Keenan RD, Ainsworth J, Khan N et al. (2001) Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol 115:428–434PubMedCrossRefGoogle Scholar
  273. 73.
    Szmania S, Galloway A, Bruorton M et al. (2001) Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 98:505–512PubMedCrossRefGoogle Scholar
  274. 74.
    Khattab B, Lindenmaier W, Link H (1997) Mapping of HLA class II restricted T cell epitope domains within the matrix protein pp65 of the human cytomegalovirus using recombinant proteins. J Med Virol 52:68–76PubMedCrossRefGoogle Scholar
  275. 75.
    Rooney CM, Smith CA, Ng CY et al. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549–1555PubMedGoogle Scholar
  276. 76.
    Kuehnle I, Huls MH, Liu Z et al. (2000) CD20 monoclonal antibody (rituximab. for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95/4:1502–1505PubMedGoogle Scholar
  277. 77.
    Ljungman P, Wang FZ, Clark DA et al. (2000) High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 111/3:774–781PubMedCrossRefGoogle Scholar
  278. 78.
    Wainwright MS, Martin PL, Morse RP et al. (2001) Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol 50/5:612–619PubMedCrossRefGoogle Scholar
  279. 79.
    Wang FZ, Linde A, Dahl H, Ljungman P (1999) Human herpesvirus 6 infection inhibits specific lymphocyte proliferation responses and is related to lymphocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant 24/11:1201–1206PubMedCrossRefGoogle Scholar
  280. 80.
    Solano C, Juan O, Gimeno C, Garcia-Conde J (1996) Engraftment failure associated with peripheral blood stem cell transplantation after B19 parvovirus infection. Blood 88/4:1515–1517PubMedGoogle Scholar
  281. 81.
    Itala M, Kotilainen P, Nikkari S, Remes K, Nikoskelainen J (1997) Pure red cell aplasia caused by B19 parvovirus infection after autologous blood stem cell transplantation in a patient with chronic lymphocytic leukemia. Leukemia 11/1:171PubMedCrossRefGoogle Scholar
  282. 82.
    Hughes WT (1984) Five-Year Absence of Pneumocystis carinii Pneumonitis in a Pediatric Oncology Center. J Infect Dis 150:305–305PubMedCrossRefGoogle Scholar
  283. 83.
    Link H, Vöhringer HF, Wingen F et al. (1992) Risikofaktoren und Prophylaxe der Pneumocystis-carinii-Pneumonie nach Knochenmarktransplantation. Med Klin 87(Suppl 1):39–42Google Scholar
  284. 84.
    Tuan IZ, Dennison D, Weisdorf DJ (1992) Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 10/3:267–272PubMedGoogle Scholar
  285. 85.
    Vasconcelles MJ, Bernardo MV, King C, Weiler EA, Antin JH (2000) Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 6/1:35–43PubMedCrossRefGoogle Scholar
  286. 86.
    Neiman P, Wasserman PB, Wentworth BB et al. (1973) Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation. Transplantation 15:478–485PubMedCrossRefGoogle Scholar
  287. 87.
    NN (1991) Pneumocystis-carinii Pneumonie bei Immunsuppression —Prophylaxe und Therapie in der Hämatologie, Onkologie und bei Organtransplantation. De Gruyter, Berlin New YorkGoogle Scholar
  288. 88.
    Slavin MA, Meyers JD, Remington JS, Hackman RC (1994) Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant 13/5:549–557PubMedGoogle Scholar
  289. 89.
    Small TN, Leung L, Stiles J et al. (2000) Disseminated toxoplasmosis following T cell-depleted related and unrelated bone marrow transplantation. Bone Marrow Transplant 25/9:969–973PubMedCrossRefGoogle Scholar
  290. 90.
    Link H, Reinhard U, Walter E, Wernet P, Schneider EM, Fischbach H, Blaurock M, Wilms K, Niethammer D, Ostendorf P (1986) Lung diseases after bone marrow transplantation. A study of clinic, radiology, histology, lung function and immunology. Klin Wochenschr 64:595–614PubMedCrossRefGoogle Scholar
  291. 91.
    Griese M, Rampf U, Hofmann D et al. (2000) Pulmonary complications after bone marrow transplantation in children: twenty-four years of experience in a single pediatric center. Pediatr Pulmonol 30/5:393–401PubMedCrossRefGoogle Scholar
  292. 92.
    Ho VT, Weiler E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ (2001) Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7/4:223–229PubMedCrossRefGoogle Scholar
  293. 93.
    Barrett A (1982) Total body irradiation (TBI. before marrow transplantation in leukemia — a cooperative study from the European Group For Bone Marrow Transplantation. Brit J Radiol 55:562–567PubMedCrossRefGoogle Scholar
  294. 94.
    Bortin MM, Kay HEM, Gale RP, Rimm AA (1982) Factors associated with interstitial pneumonitis following bone marrow transplantation for acute leukaemia. Lancet 1:437–439PubMedCrossRefGoogle Scholar
  295. 95.
    Vitale V, Bacigalupo A, van Lint MT et al. (1983) Factionated total body irradiation in marrow transplantation for leukaemia. Br J Haematol 55:547–554PubMedCrossRefGoogle Scholar
  296. 96.
    Wingard JR, Mellits ED, Sostrin MB et al. (1988) Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. Medicine (Baltimore) 67:175–186Google Scholar
  297. 97.
    Boeckh M, Berrey MM, Bowden RA et al. (2001) Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 184:350–354PubMedCrossRefGoogle Scholar
  298. 98.
    Legrand F, Berrebi D, Houhou N et al. (2001) Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 27:621–626PubMedCrossRefGoogle Scholar
  299. 99.
    Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A (2001) Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 32:1290–1297PubMedCrossRefGoogle Scholar
  300. 100.
    McDonald GB, Hinds MS, Fisher LD et al. (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255–267PubMedGoogle Scholar
  301. 101.
    Frickhofen N, Wiesneth M, Jainta C et al. (1998) Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994 83:-2004Google Scholar
  302. 102.
    Locasciulli A, Alberti A, De Bock R et al. (1994) Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT Group — Infectious Diseases Working Party) Bone Marrow Transplant 14/5:833–837PubMedGoogle Scholar
  303. 103.
    Caselitz M, Link H, Hein R et al. (1997) Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 27:572–577PubMedCrossRefGoogle Scholar
  304. 104.
    Lau GK, Lok AS, Liang RH et al. (1997) Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 25/6:1497–1501PubMedCrossRefGoogle Scholar
  305. 105.
    Guidelines (2000) for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 49 (RR-10): 1–125. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm Google Scholar
  306. 106.
    Dykewicz CA (2001) Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 33:139–144PubMedCrossRefGoogle Scholar
  307. 107.
    Schmeiser T, Kurrle E, Arnold R, Krieger D, Heit W, Heimpel H (1988) Antimicrobial prophylaxis in neutropenic patients after bone marrow transplantation. Infection 16:19–24PubMedCrossRefGoogle Scholar
  308. 108.
    Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330(17): 1240–1241PubMedCrossRefGoogle Scholar
  309. 109.
    Cruciani M, Rampazzo R, Malena M et al. (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23/4:795–805PubMedCrossRefGoogle Scholar
  310. 110.
    Kirkpatrick BD, Harrington SM, Smith D et al. (1999) An outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit. Clin Infect Dis 29/5:1268–1273PubMedCrossRefGoogle Scholar
  311. 111.
    Sullivan KM (1996) Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin. Clin Ther 18(Suppl B): 126–136PubMedCrossRefGoogle Scholar
  312. 112.
    Wolff SN, Fay JW, Herzig RH et al. (1993) High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 118:937–942PubMedGoogle Scholar
  313. 113.
    Mayfield JL, Leet T, Miller J, Mundy LM (2000) Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 31/4:995–1000PubMedCrossRefGoogle Scholar
  314. 114.
    Gluckman E, Lotsberg J, Devergie A et al. (1983) Prophylaxis of herpes infection after bone marrow transplantation by oral acyclovir. Lancet II: 706–708CrossRefGoogle Scholar
  315. 115.
    Wade JC, Newton B, Flournoy N, Meyers JD (1984) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 100:823–828PubMedGoogle Scholar
  316. 116.
    Kanda Y, Mineishi S, Saito T et al. (2001) Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28:689–692PubMedCrossRefGoogle Scholar
  317. 117.
    Weems JJ, Jr., Davis BJ, Tablan OC et al. (1987) Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hématologie malignancy. Infect Control 8:71–75PubMedGoogle Scholar
  318. 118.
    Opal SM, Asp AA, Cannady PB Jr et al. (1986) Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 153:634–637PubMedCrossRefGoogle Scholar
  319. 119.
    Sullivan KM, Dykewicz CA, Longworth DL et al. (2001) Tl — Preventing opportunistic infections in after hematopoeitic stem cell transplantation — the centers of disease control an prevention, infectious diseases society of America, and American Society for Blood and Bone Marrow Transplantation Practice Guidelines and Beyond. Am Society of Hematology (Education Program Book, pp 392–413)Google Scholar
  320. 120.
    Slavin MA, Osborne B, Adams R et al. (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 171/6:1545–1552PubMedCrossRefGoogle Scholar
  321. 121.
    Goodman JL, Winston DJ, Greenfield RA et al. (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851PubMedCrossRefGoogle Scholar
  322. 122.
    Link H, Vöhringer HF, Wingen F et al. (1993) Pentamidine aerosol for prophylaxis of pneumocystis carinii pneumonia after bone marrow transplantation. Bone Marrow Transplant 11:403–406PubMedGoogle Scholar
  323. 123.
    Burgers JA, Sluiters JF, de Jong DW et al. (2001) Pseudoparasitic pneumonia after bone marrow transplantation. Neth J Med 59:170–176PubMedCrossRefGoogle Scholar
  324. 124.
    Schmitz N, Linch DC, Dreger P et al. (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation vs. autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353–357PubMedCrossRefGoogle Scholar
  325. 125.
    Klumpp TR, Mangan KF, Goldberg SL et al. (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 13/6:1323–1327PubMedGoogle Scholar
  326. 126.
    Gisselbrecht C, Prentice HG, Bacigalupo A et al. (1994) Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 343:696–700PubMedCrossRefGoogle Scholar
  327. 127.
    Link H, Boogaerts MA, Carella AM et al. (1992) A controlled trial of recombinant human granulocyte-macrophage colony stimulating factor after total body irradiation, high dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 80:2188–2195PubMedGoogle Scholar
  328. 128.
    Nemunaitis J, Rabinowe SN, Singer JW et al. (1991) Recombinant granulocyte macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773–1778PubMedCrossRefGoogle Scholar
  329. 129.
    Clift RA et al. (1978) Granulocyte transfusions for the prevention of infection in patients receiving bone marrow transplantation. N Engl J Med 298:1052–1057PubMedCrossRefGoogle Scholar
  330. 130.
    Bhatia S, McCullough J, Perry EH et al. (1994) Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 34/3:226–232PubMedCrossRefGoogle Scholar
  331. 131.
    Grigg A, Vecchi L, Bardy P, Szer J (1996) G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepsis. Aust N Z J Med 26/6:813–818PubMedGoogle Scholar
  332. 132.
    Ljungman P, Fridell E, Lonnqvist B et al. (1989) Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 159/4:610–615PubMedCrossRefGoogle Scholar
  333. 133.
    Hammarstrom V, Pauksen K, Azinge J, Oberg G, Ljungman P (1993) Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft vs. host reaction. Support Care Cancer 1/4:195–199PubMedCrossRefGoogle Scholar
  334. 134.
    Ljungman P, Wiklund-Hammarsten M, Duraj V et al. (1990) Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 162/2:496–500PubMedCrossRefGoogle Scholar
  335. 135.
    Ljungman P, Duraj V, Magnius L (1991) Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 7/2:89–93PubMedGoogle Scholar
  336. 136.
    Ljungman P, Cordonnier C, De Bock R et al. (1994) Immunization practices after BMT in Europe. Bone Marrow Transplant EBMT, Harrogate: 135Google Scholar
  337. 137.
    Angulo FJ, Glaser CA, Juranek DD et al. (1994) Caring for pets of immunocompromised persons. J Am Vet Med Assoc 205/12:1711–1718PubMedGoogle Scholar
  338. 138.
    Ljungman P, Cordonnier C, De Bock R et al. (1995) Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 15:455–460PubMedGoogle Scholar
  339. 139.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRefGoogle Scholar
  340. Barnes DG, Timoney AG, Moulas G, Shaw PJ, Sanderson PJ (1992) Correlation of bacteriological flora of the urethra, glans and perineum with organisms causing urinary tract infection in the spinal injured male patient. Paraplegia 30/12:851–854PubMedCrossRefGoogle Scholar
  341. Cardenas DD, Hooton TM (1995) Urinary tract infection in persons with spinal cord injury. Arch Phys Med Rehabil 76/3:272–280PubMedCrossRefGoogle Scholar
  342. Donovan WH, Hull R, Rossi CD (1996) Analysis of gram negative recolonization of the neuropathic bladder among patients with spinal cord injuries. Spinal Cord 34/10:587–591PubMedCrossRefGoogle Scholar
  343. Gerner HJ (1992) Die Querschnittlähmung. Blackwell, BerlinGoogle Scholar
  344. Lüscher N (1988) Dekubitalulzera der Beckenregion. Huber, Bern StuttgartGoogle Scholar
  345. Prieto-Fingerhut T, Banovac K, Lynne CM (1997) A study comparing sterile and nonsterile urethral catheterization in patients with spinal cord injury. Rehabil Nurs 22/6:299–302PubMedGoogle Scholar
  346. Sapico FL, Ginunas VJ, Thornhill-Joynes M et al. (1986) Quantitative microbiology of pressure sores in different stages of healing. Diagn Microbiol Infect Dis 5/1:31–38PubMedCrossRefGoogle Scholar
  347. Seiler WO, Stahelin HB, Sonnabend W (1979) Einfluss aerober und anaerober Keime auf den Heilungsverlauf von Dekubitalulzera. Schweiz Med Wochenschr 109/42:1594–1599PubMedGoogle Scholar
  348. Shekelle PG, Morton SC, Clark KA, Pathak M, Vickrey BG (1999) Systematic review of risk factors for urinary tract infection in adults with spinal cord dysfunction. J Spinal Cord Med 22/4:258–72PubMedGoogle Scholar
  349. Wagner J, Xander LU (1991) Wichtige Erreger von Wundinfektionen. In: Häring R (Hrsg) Infektionsverhütung in der Chirurgie. Blackwell, Berlin, S 91–96Google Scholar
  350. Barnett BJ, Stephens DS (1997) Urinary tract infection: an overview. Am J Med Sci 314/4:245–249PubMedCrossRefGoogle Scholar
  351. Borrego F, Gleckman R (1997) Principles of antibiotic prescribing in the elderly. Drugs Aging 11/1:7–18PubMedCrossRefGoogle Scholar
  352. Boscia JA, Abrutyn E, Kaye D (1987) Asymptomatic bacteriuria in elderly persons: Treat or not treat? Ann Intern Med 106:764–766PubMedGoogle Scholar
  353. Briihl P (1995) Nosokomiale Harnwegsinfektionen. Einschränkung durch Prävention. Krankenhausarzt 68:430–436Google Scholar
  354. Falsey AR, Bentley DW (1992) Control of infections. In: Evans JG, Williams TF (ed) Oxford textbook of geriatric medicine. Oxford Univ Press, Oxford, pp 70–77Google Scholar
  355. Farmer JA, Torre G (1997) Endocarditis. Curr Opin Cardiol 12/2:123–30PubMedCrossRefGoogle Scholar
  356. Garibaldi RA, Brdodine S, Matsumiya S (1981) Infections among patients in nursing homes: Policies, prevalence, and problems. N Engl J Med 305:731–735PubMedCrossRefGoogle Scholar
  357. Garibaldi RA, Neuhaus EG, Nurse BA (1988) Infections in the elderly. In: Rowe JW, Besdine RW (eds) Geriatric medicine, 2nd edn. Little, Brown, Boston Toronto, pp 302–23Google Scholar
  358. Gleckman RA, Czachor JS (1989) Reviewing the safe use of antibiotics in the elderly. Geriatrics 44:33–39PubMedGoogle Scholar
  359. Grau S, Monterde J, Drobnic L, Salvado M (1997) Management of urinary tract infections: a comprehensive review. Pharm World Sci 19/5:236–245PubMedCrossRefGoogle Scholar
  360. Gsell O (1986) Infektionskrankheiten in der Geriatrie. In: Martin E, Junod J-P (Hrsg) Lehrbuch der Geriatrie. Huber, Bern, S 179–217Google Scholar
  361. Hager K, Ruwe A (1998) Clostridium difficile Toxin-assoziierte Diarrhöen in der Geriatrie. Z Gerontol Geriatr 1:16–21CrossRefGoogle Scholar
  362. Houston MS, Silverstein MD, Suman VJ (1997) Risk factors for 30-day mortality in elderly patients with lower respiratory tract infection. Community-based study. Arch Intern Med 157/19:2190–2195PubMedCrossRefGoogle Scholar
  363. Keating HJ, Klimek JJ, Levine DS, Kiernan FJ (1984) Effect of aging on the clinical significance of fever in ambulatory adult patients. JAGS 32:282–287Google Scholar
  364. Lane TW (1983) Urinary tract infections in the elderly. In: McCue JD (ed) Medical care of the elderly. Collamore, Lexington, 287–295Google Scholar
  365. Leistevuo T, Isoaho R, Klaukka T, Kivela SL, Huovinen P (1997) Prescription of antimicrobial agents to elderly people in relation to the type of infection. Age Ageing 26/5:345–51PubMedCrossRefGoogle Scholar
  366. Lode H, Seiler W, Ulimann U (Hrsg) (1988) Infektionen beim alten Patienten. Zuckschwerdt, MünchenGoogle Scholar
  367. Marrie TJ (1996) Pneumonia in the elderly. Curr Opin Pulm Med 2/3:192–197PubMedCrossRefGoogle Scholar
  368. Metlay JP, Schulz R, Li YH et al. (1997) Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 157/13:1453–1459PubMedCrossRefGoogle Scholar
  369. Mims AD, Norman DC, Yamamura RH, Yoshikawa TT (1990) Clinically inapparent (asymptomatic) bacteriuria in ambulatory elderly men: epidemiological, clinical and microbiological findings. JAGS 38:1209–1214Google Scholar
  370. Morike K, Schwab M, Klotz U (1997) Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging 10/4:259–277PubMedCrossRefGoogle Scholar
  371. Nicholson KG, Kent J, Hammersley V, Cancio E (1997) Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 315(7115): 1060–1064PubMedGoogle Scholar
  372. Nicolle LE (1997) Asymptomatic bacteriuria in the elderly. Infect Dis Clin N Am 11/3:647–662CrossRefGoogle Scholar
  373. Niederman MS (1995) Respiratory infections in the 1990 s [editorial]. Curr Opin Pulm Med 1/3:155–162PubMedGoogle Scholar
  374. Norman DC, Bradley SF, Dorinsky PM, Verghese A (1997) Treating respiratory infections in the elderly: current strategies and considerations. Geriatrics 52(Suppl 1): 1–28Google Scholar
  375. Norman DC, Grahn D, Yoshikawa TT (1985) Fever and aging. JAGS 33:859–863Google Scholar
  376. Panknin HT (1996) Aktivierende Krankenpflege — eine Möglichkeit der Infektionsprophylaxe. Altenpflege 8:521–526Google Scholar
  377. Phair J, Kauffman Ca, Bjornson A, Adams L, Linnemann C (1978) Failure to respond to influenza vaccine in the aged; correlation with B-cell number and function. J Lab Clin Med 92:822–628PubMedGoogle Scholar
  378. Puisieux F, Defrennes R, Salomez Granier F, Dewailly P (1997) [Incidence and consequences of nosocomial infections in a geriatric short-stay department] Presse Méd 26/36:1708–1713 (französisch)PubMedGoogle Scholar
  379. Rüden H (1995) Nosokomiale Infektionen in Deutschland: Erfassung und Prävention (NIDEP-Studie);Teil 1: Prävalenz nosokomialer Infektionen; Qualitätssicherung in der Krankenhaushygiene. Nomos, Baden-BadenGoogle Scholar
  380. Statistisches Bundesamt (1997) Statistisches Jahrbuch für die Bundesrepublik Deutschland. Metzer&Poeschel, Stuttgart, S 441–442Google Scholar
  381. Sunderkotter C, Kalden H, Luger TA (1997) Aging and the skin immune system. Arch Dermatol 133/10:1256–1262PubMedCrossRefGoogle Scholar
  382. Taylor ME, Oppenheim BA (1998) Hospital-acquired infection in elderly patients. J Hosp Infect 38:245–260PubMedCrossRefGoogle Scholar
  383. Valenti WM, Trudeil RG, Bentley DW (1978) Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged. N Engl JMed 298:1108–11CrossRefGoogle Scholar
  384. Veyssier P (1997) Infections chez le sujet agé. Presse Méd 26:32–38 (französisch)PubMedGoogle Scholar
  385. Vogel F, Panknin H-T, Reetz K-P (1998) Infektionen in Altenpflegeeinrichtungen. Med Dialog 2:1–3Google Scholar
  386. Werner H, Krings D (1993) Besonderheiten der Antibiotikatherapie im Alter. Fortschr Med 111:134–138PubMedGoogle Scholar
  387. Wood CA, Abrutyn E (1996) Optimal treatment of urinary tract infections in elderly patients. Drugs Ageing 9/5:352–362CrossRefGoogle Scholar
  388. Yoshikawa TT (1997) Perspective: aging and infectious diseases: Past, present, and future. J Infect Dis 176:1053–1057PubMedCrossRefGoogle Scholar
  389. Yoshikawa TT, Norman DC (1996) Approach to fever and infection in the nursing home. JAGS 44:74–82Google Scholar
  390. Zimmer JG, Bentley DW, Valenti WM, Watson NM (1986) Systemic antibiotic use in nursing homes: a quality assessment. JAGS 34:704–710Google Scholar
  391. Arbeitskreis Blut des Bundesministeriums für Gesundheit (1998a) Humane T-Zell lymphotrope Viren Typ 1 und 2 (HTLV-I/-II). Bundesgesundheitsblatt 41/12:512–517Google Scholar
  392. Arbeitskreis Blut des Bundesministeriums für Gesundheit (1998b) Parvovirus B19. Bundesgesundheitsblatt 41/2:83–87CrossRefGoogle Scholar
  393. Arbeitskreis Blut des Bundesministeriums für Gesundheit (1998c) Creutzfeldt-Jakob-Erkrankung (CJK) bzw. humane übertragbare (transmissible) spongiforme Enzephalopathien (TSE). Bundesgesundheitsblatt 41/2:78–83CrossRefGoogle Scholar
  394. Arbeitskreis Blut des Bundesministeriums für Gesundheit (1999a) Filtration von zellulären Blutpräparaten. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 42:89–92CrossRefGoogle Scholar
  395. Arbeitskreis Blut des Bundesministeriums für Gesundheit (1999b) Yersinia enterocolitica. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 42:613–621CrossRefGoogle Scholar
  396. Arbeitskreis Blut des Bundesministeriums für Gesundheit (2000) Hepatitis-B-Virus (HBV). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 43:240–248CrossRefGoogle Scholar
  397. Arbeitskreis Blut des Bundesministeriums für Gesundheit (2001) Verfahren zur Rückverfolgung (Look-back) (gemäß § 19 Transfusionsgesetz). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44:305–316CrossRefGoogle Scholar
  398. Azzi A, Morfini M, Mannucci PM (1999) The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 13:194–204PubMedCrossRefGoogle Scholar
  399. Caspari G, Gerlich WH, Kühnl P (1996) Durch Blut übertragbare Infektionskrankheiten. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Grundlagen — Therapie-Methodik, 2. Aufl. Springer, Berlin Heidelberg New York Tokio, S 549–584Google Scholar
  400. Caspari G, Fiedler H, Hornstein C, Muss P, Gerlich WH, Lefèvre H (1999) Effekt von Vorspendenergebnissen und vertraulichem Selbstausschluss auf Prävalenz und Inzidenz von HCV bei Blutspendern des DRK-Blutspendedienstes Nordrhein-Westfalen. Infusionsther Transfusionsmed 26:293–299Google Scholar
  401. Chudy M, Budek I, Keller-Stanislawski B, McCaustland K et al. (1999) A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol 57:91–99PubMedCrossRefGoogle Scholar
  402. Diekamp U, Wehrend W, Marklof E, Kamutzky K (1996) Spenderausschlüsse,-rückstellungen und nichttransfusionsgeeignete Konserven von 2,13 Mio. Spendewilligen der Jahre 1991 bis 1994. Beitr Infusionsther Transfusionsmed 33:81–92PubMedGoogle Scholar
  403. Glück D, Kubanek B, Maurer C, Petersen N (1998) Seroconversion of HIV, HCV and HBV in blood donors in 1996 — Risk of virus transmission by blood products in Germany. A multicenter study of the Berufsverband Deutscher Transfusionsmediziner. Infusionsther Transfusionsmed 25/2–3:82–85Google Scholar
  404. Humpe A, Heermann K-H, Köhler M (1999) Infektionen mit Hepatitis-C-Virus durch Quarantäneplasma. Dtsch Ärztebl 96:A-2749-2753Google Scholar
  405. James V, Hewitt PE, Barbara JA (1999) How understanding donor behavior should shape donor selection. Transfus Med Rev 13:49–64PubMedCrossRefGoogle Scholar
  406. Jordan J, Tiangco B, Kiss J, Koch W (1998) Human parvovirus B19: prevalence of viral RNA in volunteer blood and clinical outcomes of transfusion recipients. Vox Sang 75:97–102PubMedCrossRefGoogle Scholar
  407. Kleinman S, Williams AE (1998) Donor selection procedures: is it possible to improve them?. Transfus Med Rev 12:288–302PubMedCrossRefGoogle Scholar
  408. Lapierre V, Hervé P (1999) Surveillance et effets secondaires d’une transfusion des produits sanguins labiles. Presse Méd 28/24:1327–35PubMedGoogle Scholar
  409. Montag T, Lange H, Schmidt U, Strobel J, Exner M (1999) Bakterielle Kontamination von Blutkomponenten. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 42:132–142CrossRefGoogle Scholar
  410. Pamphilon DH, Rider JR, Barbara JA, Williamson LM (1999) Prevention of transfusion-transmitted cytomegalovirus infection. Transfus Med 9/2:115–123PubMedCrossRefGoogle Scholar
  411. Regan FAM, Hewitt P, Barbara JAJ, Contreras M (2000) Prospective investigation of transfusion transmitted infection in recipients of over 20,000 units of blood. BMJ 320:403–406)PubMedCrossRefGoogle Scholar
  412. Renom P, Wibaut B, Savage C, Vannier V, Goudemand J (1999) Difficultés diagnostiques des incidents transfusionels par contamination bactérienne: à propos de deux observations. Transfus Clin Biol 6/2:124–128PubMedCrossRefGoogle Scholar
  413. Schüttler CG, Caspari G, Jursch CA et al. (2000) Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 355:41–42PubMedCrossRefGoogle Scholar
  414. Wissenschaftlicher Beirat der Bundesärztekammer und Paul-Ehrlich-Institut (2000) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Deutscher Ärzteverlag, KölnGoogle Scholar
  415. Yu MW, Mason BL, Guo ZP et al. (1995) Hepatitis C transmission associated with intravenous immunoglobulins [letter]. Lancet 345:1173–1174PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • R. Abel
    • 2
  • M. Backmund
    • 3
  • G. Caspari
    • 4
  • D. Eichenlaub
    • 3
  • K. Hager
    • 5
  • E.-R. Kuse
    • 1
  • H. Link
    • 6
  1. 1.Viszeral- und Transplantationschirurgie, Station 12 b, OE 6223Med. Hochschule HannoverHannoverGermany
  2. 2.Orthopädische UniversitätsklinikHeidelberg-SchlierbachGermany
  3. 3.IV. Med. AbteilungStädt. Klinikum SchwabingMünchenGermany
  4. 4.Institut für TransfusionsmedizinBrandenburg—W&T GmbHBrandenburg a. d. HavelGermany
  5. 5.Klinik für Medizinische Rehabilitation und GeriatrieHenriettenstiftung-KrankenhausHannover (Kirchrode)Germany
  6. 6.Medizinische Klinik IWestpfalz-KlinikumKaiserslauternGermany

Personalised recommendations